share_log

Calculating The Intrinsic Value Of Tellgen Corporation (SZSE:300642)

tellgen corporation(SZSE:300642)の内在価値の計算

Simply Wall St ·  10/02 22:28

Key Insights

  • Using the 2 Stage Free Cash Flow to Equity, Tellgen fair value estimate is CN¥12.78
  • Current share price of CN¥14.86 suggests Tellgen is potentially trading close to its fair value
  • When compared to theindustry average discount of -507%, Tellgen's competitors seem to be trading at a greater premium to fair value

In this article we are going to estimate the intrinsic value of Tellgen Corporation (SZSE:300642) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Believe it or not, it's not too difficult to follow, as you'll see from our example!

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.

Crunching The Numbers

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) estimate

2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
Levered FCF (CN¥, Millions) CN¥68.4m CN¥79.3m CN¥88.7m CN¥96.9m CN¥103.9m CN¥110.1m CN¥115.6m CN¥120.7m CN¥125.4m CN¥129.9m
Growth Rate Estimate Source Est @ 21.35% Est @ 15.80% Est @ 11.91% Est @ 9.19% Est @ 7.29% Est @ 5.96% Est @ 5.03% Est @ 4.37% Est @ 3.92% Est @ 3.60%
Present Value (CN¥, Millions) Discounted @ 7.5% CN¥63.7 CN¥68.6 CN¥71.4 CN¥72.5 CN¥72.3 CN¥71.3 CN¥69.6 CN¥67.6 CN¥65.3 CN¥62.9

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥685m

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.5%.

Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥130m× (1 + 2.9%) ÷ (7.5%– 2.9%) = CN¥2.9b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥2.9b÷ ( 1 + 7.5%)10= CN¥1.4b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is CN¥2.1b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of CN¥14.9, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

big
SZSE:300642 Discounted Cash Flow October 3rd 2024

The Assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Tellgen as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.5%, which is based on a levered beta of 0.938. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Tellgen

Strength
  • Debt is not viewed as a risk.
  • Balance sheet summary for 300642.
Weakness
  • Earnings declined over the past year.
  • Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.
  • Current share price is above our estimate of fair value.
Opportunity
  • 300642's financial characteristics indicate limited near-term opportunities for shareholders.
  • Lack of analyst coverage makes it difficult to determine 300642's earnings prospects.
Threat
  • Paying a dividend but company has no free cash flows.
  • See 300642's dividend history.

Looking Ahead:

Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Tellgen, we've compiled three essential factors you should assess:

  1. Risks: Case in point, we've spotted 4 warning signs for Tellgen you should be aware of, and 2 of them don't sit too well with us.
  2. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
  3. Other Top Analyst Picks: Interested to see what the analysts are thinking? Take a look at our interactive list of analysts' top stock picks to find out what they feel might have an attractive future outlook!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SZSE every day. If you want to find the calculation for other stocks just search here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする